Key facts
- This page summarizes Sharon O'Keefe's Form 4 filing for Apollo Endosurgery, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 04 Apr 2023, 19:56.
Sharon O'Keefe - 04 Apr 2023 Form 4 Insider Report for Apollo Endosurgery, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 04 Apr 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Apr 2023, 19:56:11 UTC
- Prior SEC filing
- 14 Nov 2022
- Next SEC filing
- 13 Nov 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian Szymczak - Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Sharon O'Keefe filed Form 4 for Apollo Endosurgery, Inc. on 04 Apr 2023.
Change
- Previous filing in this sequence was filed on 14 Nov 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
APEN
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -35,604
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 04 Apr 2023
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Sharon O'Keefe is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation ("Parent") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger between Issuer and Merger Sub on April 4, 2023 (the "Merger"), at the effective time of the Merger (the "Effective Time"), each outstanding restricted stock unit award granted under any Issuer Stock Plan (each, an "Issuer RSU"), whether vested but unsettled or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the right to receive $10.00 in cash, without interest (the "Merger Consideration"), less applicable taxes and authorized deduction [footnote continues in footnote 2 below]
Footnote F2
and (2) the aggregate number of shares of Issuer common stock, par value $0.001 per share ("Issuer Common Stock") underlying such Issuer RSU, less applicable taxes and authorized deductions.